Top ▲

Pyoderma gangrenosum

GtoPdb Disease Summaries

This section gives an overview of the disease, and where available shows the following:

  • Synonyms: Shows known synonyms for the disease.
  • Description: Gives a basic description/definition of the disease.
  • Database Link: External links to the same disease at the Disease Ontology, OMIM or Orphanet sites.
  • Immunopharmacology comments: General comments about the target's role in immunopharmacology, provided by GtoImmuPdb curators.
  • Associated with: Counts are displayed for the total targets the disease is associated with in GtoPdb. The counts of targets and ligands of immunological relevance associated to the disease are also shown.

More information can be found in the help pages.

✖
Disease ID:1240
Name:Pyoderma gangrenosum
Associated with:0 target
1 immuno-relevant ligand
Description
A sterile inflammatory ulcerative condition of the skin, likely due to an overactive immune reaction to skin trauma, or another disease, characterised by neutrophil infiltration and mucopurulent or hemorrhagic exudate. A significant proportion of cases are comorbid with autoimmune conditions.
Database Links
Disease Ontology: DOID:8553
Orphanet: ORPHA48104

Targets

GtoPdb Disease Summaries - Targets

Click on the target name to link to its detailed view page

Where available, information is display on the role of the target in the disease; drugs which target the disease and their therapeutic use and side-effects.

If there is mutation data curated in GtoPdb this is indicated, with a link back to the appropriate section on the target detailed view page

Immuno ligand interactions - If available, a table of immuno-relevant ligands is shown. These ligands have been curated as having an association to the disease and possess interaction data with the target in GtoPdb. The approval status of the ligand is shown, along with curator comments and an indication of whether the target is considered the primary target of the ligand.

More information can be found in the help pages.

✖
Key to terms and symbols

No target related data available for Pyoderma gangrenosum

Ligands

GtoPdb Disease Summaries - Ligands

Click ligand name to view ligand summary page

  • Approved: If the ligand is an approved drug this is indicated, along with approval bodies.
  • Immuno: Immuno icon indicates the ligand is immuno-relevant

Click the arrow in the final column to expand comments

  • Immuno Disease Comments: Curatorial comments specifically added as part of GtoImmuPdb. They give more information on the association between the ligand and disease in the context of immunopharmacology.
  • Clinical Use: General clinical comments relating to the ligand and may not necessarily be specific to the disease in question. With hyperlink to more details on the ligand summary pages.
  • Bioactivty Comments: Curatorial comments specifically about the compounds biological activity - with hyperlink to more details on the ligand summary pages.

More information can be found in the help pages.

✖
Key to terms and symbols Click ligand name to view ligand summary Click column headers to sort
Ligand References Clinical and Disease comments
etrasimod
Immuno Disease Comments: Phase 2 clinical candidate for this condition (see NCT03072953).
Clinical Use: Etrasimod (APD334) was advanced to clinical trial in patients with moderately to severely active ulcerative colitis (see NCT02536404). It was approved for this indication by the FDA in October 2023. | View clinical data
Bioactivity Comments: In in vitro β-arrestin recruitment assays APD334 has no measurable activity at S1P2 and S1P3 receptors, and low activity at S1P4 receptors [1]. EC50 for S1P5 receptors is around 4-fold lower than for the primary target S1P1. APD334 has similar ability to induce cAMP accumulation across S1P1 receptors from species including human, rat, mouse, monkey and dog. APD334 produces robust lymphocyte lowering in several preclinical species, and is effective in a mouse experimental autoimmune encephalomyelitis (EAE) model of multiple sclerosis [1]. | View biological activity

References

Show »

1. Buzard DJ, Kim SH, Lopez L, Kawasaki A, Zhu X, Moody J, Thoresen L, Calderon I, Ullman B, Han S et al.. (2014) Discovery of APD334: Design of a Clinical Stage Functional Antagonist of the Sphingosine-1-phosphate-1 Receptor. ACS Med Chem Lett, 5 (12): 1313-7. [PMID:25516790]